Publication Topic

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, … Dingley KH, et al. 2015. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett 6(8):936–941; doi: 10.1021/acsmedchemlett.5b00207. PMID: 26288697.

Haws LC, Scott PK, Unice KM, Gough M, Harris MA, Staskal DF, Paustenbach DJ, Pavuk M. Are dioxin body burdens surrogates for other risk factors in associations between dioxin and diabetes? Dioxin 2006, Oslo, Norway, August 2006.